Maxcyte (MXCT) Cash & Equivalents (2020 - 2026)

Maxcyte (MXCT) has 7 years of Cash & Equivalents data on file, last reported at $14.6 million in Q1 2026.

• On a quarterly basis, Cash & Equivalents fell 37.75% year-over-year to $14.6 million in Q1 2026; TTM through Mar 2026 was $14.6 million, a 37.75% decrease from a year earlier, with the FY2025 full-year figure at $20.1 million, down 28.04% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $14.6 million, down from $20.1 million in the prior quarter.
• Over the last five years, Cash & Equivalents for MXCT reached as high as $239.8 million in Q1 2022 and fell as low as $11.1 million in Q4 2022.
• Historically, Cash & Equivalents has averaged $47.2 million across 5 years, with a median of $37.0 million in 2024.
• On a YoY basis, Cash & Equivalents climbed as much as 320.3% in 2023 and fell as far as 84.22% in 2023.
• Year by year, Cash & Equivalents stood at $11.1 million in 2022, then surged by 320.3% to $46.5 million in 2023, then slumped by 40.04% to $27.9 million in 2024, then fell by 28.04% to $20.1 million in 2025, then dropped by 27.45% to $14.6 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $14.6 million in Q1 2026, $20.1 million in Q4 2025, and $13.0 million in Q3 2025.